BioLife Solutions, Inc. Q1 FY2026 earnings call

Good afternoon, welcome to the call. Roderick DeGrief mentioned 2026 started solid with 25% revenue growth and 15% adjusted EBITDA growth vs prior year. BPM drove growth, over 85% of revenue. Market position strengthened with BPM in 17 approved therapies and visibility into 9 more. Cell seal vials and HPL lines growing. Focus on cross-selling and strategic initiatives. Operating leverage seen. Mentioned cell therapy landscape trends.

Total revenue reached $27.5 million, increasing 25% year-over-year. Adjusted EBITDA was $6.2 million, or 22% of revenue. BPM represents over 85% of total revenue. Gap gross margin for Q1 2026 was 64%, adjusted gross margin was 64%.

Affirming 2026 guidance: revenue 112.5 to 115 million, growth 17 - 20%. Expect continued operating and adjusted EBITDA margin expansion, full year positive gap net income.

Gross margin and adjusted EBITDA as percent of revenue declined due to bag yield dynamics. Also, biotech funding impact on early stage customers (though minimal).

Q: On bags, clarification on margins and scrap.

A: Work with customers, 90-day notice, on track.

Q: Sector level biotech funding.

A: Funding impact minimal on BioLife, bulk revenue from well-capitalized firms.

Q: Cryo case commercial.

A: Received award, many validations, waiting for customer announcement.

Q: Homebrew share in cell therapy.

A: Numbers in favor of BioLife, hard to justify homebrew.

Q: R&D expense.

A: Related to Center of Excellence and internal projects.

Q: Commercial BPM customers revenue.

A: Target 55% realistic near term.

Q: Plurisix and QKIND deal.

A: No direct revenue impact from that deal.